Cargando…

Updates in therapeutic drug monitoring in inflammatory bowel disease

Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodhia, Nilesh, Rao, Shanti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185221/
https://www.ncbi.nlm.nih.gov/pubmed/35800180
http://dx.doi.org/10.3748/wjg.v28.i21.2282
_version_ 1784724670479597568
author Lodhia, Nilesh
Rao, Shanti
author_facet Lodhia, Nilesh
Rao, Shanti
author_sort Lodhia, Nilesh
collection PubMed
description Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM.
format Online
Article
Text
id pubmed-9185221
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-91852212022-07-06 Updates in therapeutic drug monitoring in inflammatory bowel disease Lodhia, Nilesh Rao, Shanti World J Gastroenterol Minireviews Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM. Baishideng Publishing Group Inc 2022-06-07 2022-06-07 /pmc/articles/PMC9185221/ /pubmed/35800180 http://dx.doi.org/10.3748/wjg.v28.i21.2282 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Lodhia, Nilesh
Rao, Shanti
Updates in therapeutic drug monitoring in inflammatory bowel disease
title Updates in therapeutic drug monitoring in inflammatory bowel disease
title_full Updates in therapeutic drug monitoring in inflammatory bowel disease
title_fullStr Updates in therapeutic drug monitoring in inflammatory bowel disease
title_full_unstemmed Updates in therapeutic drug monitoring in inflammatory bowel disease
title_short Updates in therapeutic drug monitoring in inflammatory bowel disease
title_sort updates in therapeutic drug monitoring in inflammatory bowel disease
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185221/
https://www.ncbi.nlm.nih.gov/pubmed/35800180
http://dx.doi.org/10.3748/wjg.v28.i21.2282
work_keys_str_mv AT lodhianilesh updatesintherapeuticdrugmonitoringininflammatoryboweldisease
AT raoshanti updatesintherapeuticdrugmonitoringininflammatoryboweldisease